Karad And Patil Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 4 Days
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 3274.43%
- Profit Growth 2128.83%
- Ebitda -23680.73%
- Net Worth 81.83%
- Total Assets 1380.12%
About Karad And Patil Pharmaceuticals
Karad And Patil Pharmaceuticals Private Limited (KAPPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 27 January 2021 (Four years 4 days old ). Its registered office is in Latur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Poonam Patil and Keshav Karad serve as directors at the Company.
Company Details
-
Location
Latur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299PN2021PTC198088
-
Company No.
198088
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Jan 2021
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Karad And Patil Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poonam Patil
|
Director | 27-Jan-2021 | Current |
|
Keshav Karad
|
Director | 01-Apr-2023 | Current |
Financial Performance of Karad And Patil Pharmaceuticals.
Karad And Patil Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 3274.43% increase. The company also saw a substantial improvement in profitability, with a 2128.83% increase in profit. The company's net worth Soared by an impressive increase of 81.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Karad And Patil Pharmaceuticals?
In 2021, Karad And Patil Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Grey Force Distribution Private LimitedPoonam Patil is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Karad And Patil Pharmaceuticals?
Karad And Patil Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Karad And Patil Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Karad And Patil Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
